Table 3.

Factors independently associated with ICH

Effectχ2HR (95% CI)
Region 47.41  
 Asia vs Europe 3.19 (2.18-4.68) 
 Latin America vs Europe 1.57 (1.02-2.43) 
 North America vs Europe 0.91 (0.57-1.44) 
Randomized treatment (apixaban vs warfarin) 27.97 0.42 (0.30-0.58) 
Age (5-y increase) 25.54 1.25 (1.15-1.36) 
Prior stroke/TIA 13.47 1.83 (1.33-2.52) 
Aspirin at randomization 3.97 1.37 (1.01-1.86) 
Effectχ2HR (95% CI)
Region 47.41  
 Asia vs Europe 3.19 (2.18-4.68) 
 Latin America vs Europe 1.57 (1.02-2.43) 
 North America vs Europe 0.91 (0.57-1.44) 
Randomized treatment (apixaban vs warfarin) 27.97 0.42 (0.30-0.58) 
Age (5-y increase) 25.54 1.25 (1.15-1.36) 
Prior stroke/TIA 13.47 1.83 (1.33-2.52) 
Aspirin at randomization 3.97 1.37 (1.01-1.86) 

c-index: 0.733. c-index by region: North America: 0.713, Latin America: 0.655, Europe: 0.667, Asia: 0.742. Other variables considered for inclusion: race, sex, weight, history of bleeding, history of anemia, history of falls within a year, coronary artery disease, hypertension, alcohol use at randomization, liver disease, creatinine clearance, hemoglobin, prior vitamin K antagonist use, and nonsteroidal anti-inflammatory drugs at randomization.

Close Modal

or Create an Account

Close Modal
Close Modal